HIV+Hep in the News

;

Trump’s federal assistance ‘pause’: Judge delays order, states confirm Medicaid portal disruptions

by | Jan 28, 2025

“This is extremely disconcerting,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, in an emailed statement. “People with HIV/AIDS depend on medications, healthcare and support services for the rest of their lives and we have to take steps to prevent HIV every day, we just can’t stop funding these programs. These lifesaving programs serve a wide array of different populations, and HIV is an infectious disease with serious health consequences if not properly addressed—we can’t overlook any community and must serve everyone.”

read more

Copay assistance is not going towards patient deductibles thus leaving people with out-of-pocket costs

by | Jan 27, 2025

In a previous interview with Contagion, Carl Schmid, executive director of the HIV+Hepatitis Policy Institute discussed the federal courts 2022 decision on copay assistance, and the Biden administration’s decision to not enforce the court’s ruling. “I guess they’re getting pressure from the big insurers and the big PBMs. And you know what I’m hearing is that the insurers are saying this leads to higher drug prices. And you know, the Biden administration has really prided itself on taking on Big Pharma and lowering drug prices. Well, this is the perfect example to lower drug prices. And I don’t think they understand it,” Schmid said.

read more

Biden’s CMS added brand PrEP to exchange RA to spur coverage, advocates mixed

by | Jan 24, 2025

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, told Inside Health Policy excluding generics from the risk adjustment is fair because they are not a large cost to an insurance company in comparison to the branded drug. If generics were included, an insurer would receive credit for spending less money than another insurer providing a higher cost brand name long-acting drug. Schmid also noted that CMS is anticipating more people will be using branded PrEP than the less expensive generic alternatives, though new forms will be coming out and all insurers must cover the treatment at zero cost sharing.

read more

Search

Pin It on Pinterest

Share This